Atazanavir/Ritonavir-Associated Erythema Multiforme in an HIV-1-Positive Patient
Recent clinical documentation published in Cureus highlights an atypical drug-induced presentation of erythema multiforme in an HIV-positive patient undergoing antiretroviral therapy, underscoring the complex immunopathogenesis of severe cutaneous adverse reactions. This case brings critical focus to how immune-mediated mucocutaneous responses complicate standard antiretroviral regimens, requiring meticulous diagnostic evaluation and coordinated specialist oversight.
- Erythema multiforme is an acute, immune-mediated mucocutaneous condition characterized by target-like skin lesions and painful mucosal ulcerations.
- Clinical management of severe drug eruptions in immunocompromised cohorts requires ruling out infectious mimics via biopsy and differential infectious workups.
Clinical Presentation and Differential Diagnosis
The patient presented with classic symptoms of a severe mucocutaneous reaction, featuring painful oral mucosal ulcerations and target-like cutaneous skin lesions. Diagnosing erythema multiforme relies primarily on clinical evaluation, as routine histopathological findings—such as epithelial edema and perivascular mononuclear cell infiltration—are frequently non-diagnostic.
For patients exhibiting progressive mucocutaneous breakdown, securing an accurate diagnosis is paramount.
Pharmacological Management and Immunological Considerations
Managing severe immune-mediated reactions in patients with human immunodeficiency virus requires balancing viral suppression with acute toxicity management. Systemic corticosteroids and supportive oral regimens represent the conventional approach for mitigating mucosal inflammation, though treatment resistance necessitates inpatient monitoring.
Healthcare facilities managing multi-drug regimens must maintain rigorous diagnostic and safety protocols to protect immunocompromised populations.
Future Trajectory in Immunocompromised Dermatological Care
As clinicians encounter more complex interactions between chronic antiviral regimens and acute immune triggers, multidisciplinary oversight remains the cornerstone of safe management.
*Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.*